Utah Medical Products, Inc.
UTMD Healthcare Medical Instruments & Supplies
Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow UTMD
Utah Medical Products, Inc. (UTMD) EV/Sales
As of 16 October 2026, Utah Medical Products, Inc. (UTMD) trades at a EV/Sales of 4.2×. Over the past ten years it has ranged from 2.3× (April 2025) to 9.3× (June 2018); the current reading is higher than 24% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | (23.12%) |
| FY2024 | 3.3× | (22.43%) |
| FY2023 | 4.2× | (21.95%) |
| FY2022 | 5.4× | (13.32%) |
| FY2021 | 6.2× | 1.64% |
| FY2020 | 6.1× | (20.31%) |
| FY2019 | 7.7× | 23.99% |
| FY2018 | 6.2× | 0.11% |
| FY2017 | 6.2× | 0.14% |
| FY2016 | 6.2× | 25.57% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | 24.61% |
| Mar 2026 | 3.0× | 18.03% |
| Dec 2025 | 2.5× | (18.41%) |
| Sep 2025 | 3.1× | 15.15% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| ZJYL Jin Medical International Ltd. compare | n/m |
| NYXH Nyxoah SA compare | 0.7× |
| OSUR OraSure Technologies, Inc. compare | 0.8× |
| EMBC Embecta Corp. compare | 1.6× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| SMTI Sanara MedTech Inc. compare | 2.9× |
| UTMD Utah Medical Products, Inc. | 4.2× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)